Fredun's profit jumps 60%, board declares 2:1 bonus
FY26 revenue hit Rs. 633.3 crore, with net profit climbing to Rs. 33.2 crore. The board also proposed a final dividend of 70 paise per share.
— 4 earlier stories on Fredun Pharmaceuticals Ltd. →What's new
- FY26 standalone revenue rose 40% to Rs. 633.3 crore; net profit surged 60% to Rs. 33.2 crore.
- The board recommended a 2:1 bonus issue and a final dividend of 70 paise per share.
- Authorised share capital will be raised from Rs. 10 crore to Rs. 50 crore, subject to shareholder approval.
Why this matters
The strong earnings beat confirms the company's growth in its pharma segment. The 2:1 bonus signals management confidence, while the five-fold increase in authorised capital creates room for future equity issuances. The results were ahead of market expectations for a micro-cap.
What we're watching
- How the market prices the bonus issue ahead of the record date.
- The company's next capital-raising plans now that authorised capital is being expanded.
- Whether the 40% revenue growth rate can be sustained into FY27.
The full read
Fredun Pharmaceuticals closed FY26 with 40% revenue growth to Rs. 633.3 crore and a 60% jump in net profit to Rs. 33.2 crore. The performance, led by its pharma and healthcare segment, came alongside a 2:1 bonus and a final dividend of 70 paise per share. The bonus aims to improve liquidity, a common move for micro-caps after strong growth. More strategically, Fredun is raising its authorised share capital five-fold, from Rs. 10 crore to Rs. 50 crore, clearing the path for future equity raises if needed. The results were strong. The corporate actions are now in motion. The open question is whether the operational growth can be sustained to fill that new capital headroom.
Questions answered
- What were Fredun Pharmaceuticals' key financial results for FY26?
- The company reported standalone revenue of Rs. 633.3 crore, a 40% year-on-year increase. Net profit grew 60% to Rs. 33.2 crore, driven by higher sales in its pharmaceutical and healthcare segment.
- What corporate actions did the board announce alongside the results?
- The board recommended a 2:1 bonus share issue, meaning shareholders will receive two new shares for every one they hold. It also proposed a final dividend of 70 paise per share.
- Why is the company increasing its authorised share capital?
- Fredun plans to raise its authorised share capital from Rs. 10 crore to Rs. 50 crore. This is a necessary procedural step to accommodate the bonus issue and to create headroom for any future equity issuances.
- Is this the first time the market is seeing these FY26 numbers?
- The rationale states the final audited numbers and the bonus confirmation constitute material new information, even though some growth had been hinted at in earlier disclosures during the year.
Story so far
All notes on FREDUN →- 25 May 2026 · 2:59 PM IST Fredun's profit jumps 60%, board declares 2:1 bonus
- today Fredun pivots to pet care and physiotherapy, guides 25-30% revenue growth for FY27
- 16d ago Fredun Pharmaceuticals posts 60% profit jump and declares 2:1 bonus
- 16d ago Fredun Pharmaceuticals lifts profit 60% and declares 2:1 bonus
- 16d ago Fredun Pharma's profit jumps 60%, declares 2:1 bonus